NEW YORK, July 27, 2016 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTC QB:TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications, announced that its abstract "Preclinical Animal Data of the SM-88 Tyrosine Isomer” has been accepted for poster presentation (display) during the European Society for Medical Oncology (ESMO) 2016 Congress, to be held in October in Copenhagen, Denmark. The abstract will also be published in the ESMO 2016 Congress Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. Dr. Gerald Sokol, an internationally recognized researcher, will present the poster at the conference.
“We are delighted that ESMO has accepted our abstract for poster presentation and look forward to this opportunity,” said Dr. Giuseppe Del Priore, Chief Medical Officer, Tyme Inc. “The prestigious ESMO annual conference is a place where clinicians and researchers from all over the world gather to share information with the goal of finding effective cancer treatments. We are delighted to be part of this important dialogue,” Del Priore continued.
Unlike traditional chemotherapy, SM-88 is designed to target only active cancer cells and to force them to be vulnerable to the body's natural defenses and processes. SM-88 is a novel combination of repurposed therapies and a unique proprietary tyrosine isomer that when administered together, have demonstrated anti-cancer activity with low toxicity in a preliminary study of 30 patients [J Clin Oncol 31, 2013 (suppl; abstr e22095)]. The Company is now reporting preclinical animal data.
The abstract is based on a preclinical animal model, with escalating repeat dosing using the tyrosine agent of SM-88.
One of the mechanisms through which SM-88 is believed to selectively kill cancer cells is by exploiting cancer’s known reliance on the Warburg Effect and other homeostatic mechanisms of defense.
For more information, visit: www.tymetechnologiesinc.com.
About Tyme Technologies
Our research and development efforts are based on a proprietary platform technology, for which we retain global IP and commercial rights. Our lead program is SM-88, a proprietary combination drug product. We believe SM-88 is a first-in-class oncology therapy that increases the power of the body’s innate defenses to utilize oxidative stress to kill cancer cells. SM-88 is designed to penetrate only living cancer cells without toxic effects and without involving healthy body tissue. We believe that SM-88’s therapeutic potential is based on its ability to increase the availability of free radicals and promote their entry into cancer cells by stripping the cancer cells of their normal barriers to these toxic electrons. SM-88 is a combination of a proprietary novel molecule with three currently-marketed drugs that are generally considered safe for their already approved indications, which are in areas other than cancer treatment.
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding Tyme’s future performance, and readers can identify forward-looking statements by sentences or passages involving the use of terms such as "anticipates," "believes," “designed,” "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "would" and similar expressions intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Tyme’s control. Forward-looking statements within this press release include, without limitation, statements regarding our drug development strategies, the therapeutic mechanisms of our drug candidates and our completed and planned clinical trials. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the factors described in the section captioned "Risk Factors" of Tyme's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 30, 2016 (available at www.sec.gov).
Contact: Lisa M. Wilson, In-Site Communications, Inc. email@example.com 917-543-9932
Source:Tyme Technologies Inc